Trump’s Executive Order Aims to Illegally Undermine Federal Independent Agencies, Shield Big Corporations from Accountability
Comments on the FDA’s Draft Guidance Regarding Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act May 25, 2018
Letter to the U.S. House of Representatives Opposing Passage of the Senate’s “False Hope” Legislation May 21, 2018
Statement by Dr. Sidney Wolfe at Press Conference Regarding Sweeping Pharmaceutical Reform Proposal Published in the British Medical Journal May 17, 2018
Letter to the U.S. House of Representatives Opposing the Newest “False Hope” Legislation March 12, 2018